CFIDS Biofilm Protocol to Remove Chronic Microbial Infestation, Toxins, and Biofilm Matrix from the Gut, Blood Vessels and Lymphatics as described by the NIH
Fig. 1: The biofilm life cycle. 1: individual cells and/or tissue matrix attaches to surface. 2: extracellular polymeric substance (EPS) is produced and attachment becomes irreversible. 3 & 4: biofilm architecture develops, collecting microbes and toxins, and matures. 5: single cells, organisms and toxins are released from the biofilm.
The National Institutes of Health estimates that 60% of all human infections and 80% of infections unresponsive to medical treatment are attributable to biofilm colonies. It appears to be common especially with the following infections: Chlamydia pneumoniae, Pseudomonas aeruginosa, Helicobacter pylori, [Lyme disease – Borrelia burgdorferi] and Candida albicans.
The protection conferred upon microorganisms by biofilms allows them to achieve a high level of antibiotic resistance, stealth and invisibility. Biofilms not only provide a physical barrier to antimicrobial agents (pharmaceutical antibiotics) and host antibodies, but facilitate the exchange of antibiotic-resistant genetic material between organisms and may contain antibiotic-degrading enzymes such as b-lactamase, effectively neutralizing incoming antibiotic molecules. The decreased growth rate of sessile microorganisms (def. Permanently attached to a substrate; not free to move about; “an attached oyster”) also reduces their antibiotic susceptibility as most antimicrobial agents require rapid cell growth in order to effectively kill or inhibit the microbes. Biofilms thus render pathogenic microorganisms enormously difficult to eradicate, and can almost single-handedly contribute to localized or systemic inflammatory reactions and delayed wound healing. Depending on the type of biofilm, one or more species of pathogens may be found embedded in the extracellular polymeric substance (def. Composed primarily of polysaccharides and can either stay attached to the cell’s outer surface, or be secreted into its growth medium). Bacterial extracellular polymeric substance (EPS) maybe a carrier of, or may have heavy metals embedded in them, thus the indication for chelation w/EDTA).
Pathogenic bacterial known to reside in biofilms include: Borrelia burgdorferi, Escherichia coli, Candida albicans, Clostridium difficile, Clostridium perfringens, Helicobacter pylori, Klebsiella pneumoniae, Legionella pneumophila, Listeria monocytogenes, Pseudomonas aeruginosa, Salmonella typhimurium, Staphylococcus aureus, Staphylococcus epidermidis, and Vibrio cholerae. The number of human diseases shown to be associated with biofilms is expanding.
Monolaurin (lauric acid) 600 mg 2 caps 2x per day
Nutiva Extra-Virgin Coconut Oil (almost 50% lauric acid by volume) 1-3 TB/day
InterFase Plus™ (broad-spectrum enzyme formula w/EDTA) 2 caps 3x/day on an empty stomach
Serrapeptase or (Serrazimes – Now Foods) 20,000 units 2x per day, or Nattokinase (a potent fibrinolytic enzyme) 100mg 1-3 times per day or Lumbrokinase
Vitamin C (ascorbic acid – Not buffered, as most of these contain metals) 500mg 4x/day
- Avoid Supplemental forms of: Magnesium, Iron and Calcium as they may feed the biofilm.
- Take a broad spectrum probiotic and prebiotic. I like the combination of Now Foods brand Gr8, 2-3 per day and their Probiotic Defense Powder, 1/4 tsp 2-4x per day. These products will help to crowd out the bad bacteria, and also help disrupt biofilm colonies along the mucus membrane.
Specific Additions based on condition:
Candida* – SF722 (10-Undecenoic Acid 50 mg) Thorne Research. This is as close as you can get to a medication and still be natural. *Do not take if you are allergic to fish.
Chlamydia pneumonia – Pneumotrophin PMG by Standard Process, Inc. 1 tab 3x/day. I use it because it helps direct the body’s attention to the lung where it is needed most.
Chronic bacterial prostatitis – Quercetin (600mg’s) and Bromelain (200mg’s) combination by Now Foods. 3-6 capsules per day. Decreases inflammation and oxidant stress in the prostate while increasing local concentrations of beta-endorphins.